Literature DB >> 25931851

Restaging of colorectal cancer and PET/CT.

Alev Çınar1, Esra Arzu Gençoğlu2, Meliha Korkmaz1.   

Abstract

Positron Emission Tomography/Computerized Tomography (PET/CT) is an important assessment method in restaging of oncology patients. Its ability to detect the metabolic/functional changes in patients with colorectal cancer during the early stages, in which morphological changes cannot be documented, is significantly superior to other imaging modalities.

Entities:  

Keywords:  Colorectal cancer; PET-CT; restaging

Year:  2013        PMID： 25931851      PMCID： PMC4379843          DOI： 10.5152/UCD.2013.42

Source DB:  PubMed          Journal:  Ulus Cerrahi Derg        ISSN： 1300-0705


  41 in total

1.  Survival factors in 186 patients younger than 40 years old with colorectal adenocarcinoma.

Authors:  J C Cusack; G G Giacco; K Cleary; B S Davidson; F Izzo; J Skibber; J Yen; S A Curley
Journal:  J Am Coll Surg       Date:  1996-08       Impact factor: 6.113

2.  The use of FDG-positron emission tomography for the evaluation of colorectal metastases of the liver.

Authors:  K N Boykin; G B Zibari; D L Lilien; R W McMillan; D F Aultman; J C McDonald
Journal:  Am Surg       Date:  1999-12       Impact factor: 0.688

3.  Number of nodes examined and staging accuracy in colorectal carcinoma.

Authors:  J H Wong; R Severino; M B Honnebier; P Tom; T S Namiki
Journal:  J Clin Oncol       Date:  1999-09       Impact factor: 44.544

4.  Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: correlation with histopathologic and CT findings.

Authors:  H Abdel-Nabi; R J Doerr; D M Lamonica; V R Cronin; P J Galantowicz; G M Carbone; M B Spaulding
Journal:  Radiology       Date:  1998-03       Impact factor: 11.105

5.  The role of whole-body positron emission tomography with [18F]fluorodeoxyglucose in identifying operable colorectal cancer metastases to the liver.

Authors:  D T Lai; M Fulham; M S Stephen; K M Chu; M Solomon; J F Thompson; D M Sheldon; D W Storey
Journal:  Arch Surg       Date:  1996-07

6.  Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer.

Authors:  F L Flanagan; F Dehdashti; O A Ogunbiyi; I J Kodner; B A Siegel
Journal:  Ann Surg       Date:  1998-03       Impact factor: 12.969

7.  Resected pulmonary metastases from colorectal cancer.

Authors:  P M McCormack; F F Attiyeh
Journal:  Dis Colon Rectum       Date:  1979 Nov-Dec       Impact factor: 4.585

8.  Clinical validation of SPECT and CT/MRI image registration in radiolabeled monoclonal antibody studies of colorectal carcinoma.

Authors:  A M Scott; H A Macapinlac; C R Divgi; J J Zhang; H Kalaigian; K Pentlow; S Hilton; M C Graham; G Sgouros; C Pelizzari
Journal:  J Nucl Med       Date:  1994-12       Impact factor: 10.057

9.  Detection of clinically unexpected malignant and premalignant tumors with whole-body FDG PET: histopathologic comparison.

Authors:  Harry Agress; Benjamin Z Cooper
Journal:  Radiology       Date:  2003-12-29       Impact factor: 11.105

10.  Postsurgical surveillance of colon cancer: preliminary cost analysis of physician examination, carcinoembryonic antigen testing, chest x-ray, and colonoscopy.

Authors:  R A Graham; S Wang; P J Catalano; D G Haller
Journal:  Ann Surg       Date:  1998-07       Impact factor: 12.969
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.